1. Home
  2. QLGN vs IMTE Comparison

QLGN vs IMTE Comparison

Compare QLGN & IMTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QLGN
  • IMTE
  • Stock Information
  • Founded
  • QLGN 1996
  • IMTE 2008
  • Country
  • QLGN United States
  • IMTE Malaysia
  • Employees
  • QLGN N/A
  • IMTE N/A
  • Industry
  • QLGN Biotechnology: Pharmaceutical Preparations
  • IMTE Consumer Electronics/Appliances
  • Sector
  • QLGN Health Care
  • IMTE Consumer Staples
  • Exchange
  • QLGN Nasdaq
  • IMTE Nasdaq
  • Market Cap
  • QLGN 3.1M
  • IMTE 3.3M
  • IPO Year
  • QLGN N/A
  • IMTE N/A
  • Fundamental
  • Price
  • QLGN $2.26
  • IMTE $1.06
  • Analyst Decision
  • QLGN
  • IMTE
  • Analyst Count
  • QLGN 0
  • IMTE 0
  • Target Price
  • QLGN N/A
  • IMTE N/A
  • AVG Volume (30 Days)
  • QLGN 209.6K
  • IMTE 1.1M
  • Earning Date
  • QLGN 11-13-2025
  • IMTE 10-21-2025
  • Dividend Yield
  • QLGN N/A
  • IMTE N/A
  • EPS Growth
  • QLGN N/A
  • IMTE N/A
  • EPS
  • QLGN N/A
  • IMTE N/A
  • Revenue
  • QLGN N/A
  • IMTE $123,337.00
  • Revenue This Year
  • QLGN N/A
  • IMTE N/A
  • Revenue Next Year
  • QLGN N/A
  • IMTE N/A
  • P/E Ratio
  • QLGN N/A
  • IMTE N/A
  • Revenue Growth
  • QLGN N/A
  • IMTE 4.75
  • 52 Week Low
  • QLGN $1.61
  • IMTE $0.51
  • 52 Week High
  • QLGN $10.45
  • IMTE $3.17
  • Technical
  • Relative Strength Index (RSI)
  • QLGN 62.69
  • IMTE 53.69
  • Support Level
  • QLGN $1.95
  • IMTE $0.93
  • Resistance Level
  • QLGN $2.16
  • IMTE $1.22
  • Average True Range (ATR)
  • QLGN 0.18
  • IMTE 0.13
  • MACD
  • QLGN 0.08
  • IMTE 0.02
  • Stochastic Oscillator
  • QLGN 43.17
  • IMTE 54.09

About QLGN Qualigen Therapeutics Inc.

Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.

About IMTE Integrated Media Technology Limited

Integrated Media Technology Ltd is engaged in the development, sale, and distribution of autostereoscopic 3D display, 3D conversion equipment, and software, development, and sale of 3D autostereoscopic technology, and the provision of 3D consultancy services. It operates through the following segments: the sale of electronic glass, sales of air-filter products, sales of Halal products, NFT, corporate, provision of consultancy and provision of new energy products and solutions.

Share on Social Networks: